These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33446227)

  • 1. Long-term experience with triheptanoin in 12 Austrian patients with long-chain fatty acid oxidation disorders.
    Zöggeler T; Stock K; Jörg-Streller M; Spenger J; Konstantopoulou V; Hufgard-Leitner M; Scholl-Bürgi S; Karall D
    Orphanet J Rare Dis; 2021 Jan; 16(1):28. PubMed ID: 33446227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review.
    Vockley J; Marsden D; McCracken E; DeWard S; Barone A; Hsu K; Kakkis E
    Mol Genet Metab; 2015; 116(1-2):53-60. PubMed ID: 26116311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.
    Vockley J; Burton B; Berry G; Longo N; Phillips J; Sanchez-Valle A; Chapman K; Tanpaiboon P; Grunewald S; Murphy E; Lu X; Cataldo J
    J Inherit Metab Dis; 2021 Jan; 44(1):253-263. PubMed ID: 32885845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders.
    Vockley J; Charrow J; Ganesh J; Eswara M; Diaz GA; McCracken E; Conway R; Enns GM; Starr J; Wang R; Abdenur JE; Sanchez-de-Toledo J; Marsden DL
    Mol Genet Metab; 2016 Nov; 119(3):223-231. PubMed ID: 27590926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study.
    Vockley J; Burton BK; Berry G; Longo N; Phillips J; Sanchez-Valle A; Chapman KA; Tanpaiboon P; Grunewald S; Murphy E; Lu X; Rahman S; Ray K; Reineking B; Pisani L; Ramirez AN
    J Inherit Metab Dis; 2023 Sep; 46(5):943-955. PubMed ID: 37276053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment.
    Vockley J; Burton B; Berry GT; Longo N; Phillips J; Sanchez-Valle A; Tanpaiboon P; Grunewald S; Murphy E; Humphrey R; Mayhew J; Bowden A; Zhang L; Cataldo J; Marsden DL; Kakkis E
    Mol Genet Metab; 2017 Apr; 120(4):370-377. PubMed ID: 28189603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major clinical events and healthcare resource use among patients with long-chain fatty acid oxidation disorders in the United States: Results from LC-FAOD Odyssey program.
    Yang E; Kruger E; Yin D; Mace K; Tierney M; Liao N; Cibelli E; Drozd D; Ross N; Deering KL; Herout P; Harshaw Q; Shillington A; Thomas N; Marsden D; Kritzer A; Vockley J
    Mol Genet Metab; 2024 May; 142(1):108350. PubMed ID: 38458123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study.
    Vockley J; Longo N; Madden M; Dwyer L; Mu Y; Chen CY; Cataldo J
    Clin Nutr ESPEN; 2021 Feb; 41():293-298. PubMed ID: 33487279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to triheptanoin therapy in critically ill patients with LC-FAOD: Report of patients treated through an expanded access program.
    Vockley J; Enns GM; Ramirez AN; Bedrosian CL; Reineking B; Lu X; Ray K; Rahman S; Marsden D
    Mol Genet Metab; 2022 Jun; 136(2):152-162. PubMed ID: 35459555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes in a series of 18 patients with long chain fatty acids oxidation disorders treated with triheptanoin for a median duration of 22 months.
    Guffon N; Mochel F; Schiff M; De Lonlay P; Douillard C; Vianey-Saban C
    Mol Genet Metab; 2021 Apr; 132(4):227-233. PubMed ID: 33610471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tutorial: Triheptanoin and Nutrition Management for Treatment of Long-Chain Fatty Acid Oxidation Disorders.
    Norris MK; Scott AI; Sullivan S; Chang IJ; Lam C; Sun A; Hahn S; Thies JM; Gunnarson M; McKean KN; Merritt JL
    JPEN J Parenter Enteral Nutr; 2021 Feb; 45(2):230-238. PubMed ID: 33085788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders Treated With Triheptanoin.
    Lee SK; Gosselin NH; Jomphe C; McKeever K; Putnam W
    Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1264-1272. PubMed ID: 35908210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triheptanoin: First Approval.
    Shirley M
    Drugs; 2020 Oct; 80(15):1595-1600. PubMed ID: 32897506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18 Months of Treatment with Triheptanoin in 2 Patients with Long Chain Fatty Acid Oxidation Disorders.
    Santos H; Vieira A; Tenente J; Carriço A; Rodrigues E
    Endocr Metab Immune Disord Drug Targets; 2023 Dec; ():. PubMed ID: 38093447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders.
    Lee SK; Gupta M; Shi J; McKeever K
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1325-1334. PubMed ID: 33789001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD).
    Vockley J; Burton B; Berry GT; Longo N; Phillips J; Sanchez-Valle A; Tanpaiboon P; Grunewald S; Murphy E; Bowden A; Chen W; Chen CY; Cataldo J; Marsden D; Kakkis E
    J Inherit Metab Dis; 2019 Jan; 42(1):169-177. PubMed ID: 30740733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: Review of 15 years Experience.
    Roe CR; Brunengraber H
    Mol Genet Metab; 2015 Dec; 116(4):260-8. PubMed ID: 26547562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-chain fatty acid oxidation disorders and current management strategies.
    Vockley J
    Am J Manag Care; 2020 Aug; 26(7 Suppl):S147-S154. PubMed ID: 32840329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders.
    Sklirou E; Alodaib AN; Dobrowolski SF; Mohsen AA; Vockley J
    Front Genet; 2020; 11():598760. PubMed ID: 33584796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.
    Gillingham MB; Heitner SB; Martin J; Rose S; Goldstein A; El-Gharbawy AH; Deward S; Lasarev MR; Pollaro J; DeLany JP; Burchill LJ; Goodpaster B; Shoemaker J; Matern D; Harding CO; Vockley J
    J Inherit Metab Dis; 2017 Nov; 40(6):831-843. PubMed ID: 28871440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.